Navamedic ASA
12.70
NOK
-0.30
(-2.31%)
ISIN
NO0010205966
Return %
Stock
S&P 500
1Y
-44.54
14.20
3Y
-68.73
81.12
5Y
-50.33
68.34
Capital Structure
NOK
•
in mil. unless spec.Working Capital
NOK
•
in mil. unless spec.Growth Rates
NOK
•
in mil. unless spec.Quarterly Revenue
NOK
•
in mil. unless spec.Quarterly Earnings Per Share
NOK
•
in mil. unless spec.Quarterly Dividends Per Share
NOK
•
in mil. unless spec.Company Description
- CEO
- Lars Minor
- Full Time Employees
- 38
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Henrik Ibsensgate 100 Oslo PS Norway 0255
- IPO Date
- Mar 30, 2006
- Website
- navamedic.com
- Similar Companies
- Business
- Navamedic ASA is a Nordic pharmaceutical company that supplies high-quality prescription medicines, consumer health products and hospital pharmaceuticals to hospitals and pharmacies across the Nordics, Benelux, Baltics and select European markets including the UK and Greece. The company offers a diverse product portfolio focused on key therapeutic areas such as obesity treatments including prescription medications, low-calorie diet meals and supplements; Parkinson's disease therapies with specialized drug delivery systems for symptom relief; antibiotics; medical nutrition for inborn errors of metabolism and gastro-related ailments; and addiction treatments encompassing Ventizolve (intranasal naloxone spray for opioid overdose reversal), Levopidon (levomethadone) and Metadon Dne (methadone) for opioid substitution therapy; alongside recent launches such as Eroxon, a clinically proven over-the-counter topical treatment for erectile dysfunction. Founded in 2002 and headquartered in Oslo, Norway, Navamedic lists on the Oslo Stock Exchange (ticker: NAVA.OL) and employs approximately 43 people, serving as a preferred partner for international firms through in-licensing and out-licensing arrangements. In July 2025, Navamedic completes the acquisition of dne pharma's business for up to NOK 225m, integrating its opioid addiction portfolio, key employees, intellectual property and contracts to expand into the growing addiction treatment sector across the Nordics and Europe, financed by NOK 110m debt from Nordea and a rights issue; the company also launches Eroxon in Danish pharmacies in 2025, enhancing its consumer health offerings.